Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLUTION: Luseogliflozin add-on vs current therapy in type 2 diabetes with moderate-to-severe renal dysfunction
jRCTs041200039Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of luseogliflozin in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in eGFRcreat from baseline to week 104. Started Nov 2020; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCTs041200039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200039.